Antidepressants for Depression

Recruiting in Palo Alto (17 mi)

Overseen by Diego A. Pizzagalli, PhD

Age: 18 - 65

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 4

Recruiting

Sponsor: Mclean Hospital

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?

The main goal of this research is to use behavioral, brain, and clinical data to determine which type of antidepressant might be optimal before people with depression start treatment.

Eligibility Criteria

Adults aged 18-64 with Major Depressive Disorder and high anhedonia symptoms, fluent in English, with good vision/hearing. Must be right-handed and able to consent to the study. Excludes pregnant women, those with metal implants or severe medical conditions, substance abuse issues, certain mental health disorders, history of adverse reactions to trial drugs (Sertraline/Bupropion), treatment-resistant depression or specific medication use.

Inclusion Criteria

My vision and hearing are normal, or corrected to be normal.

Ability to give signed, informed consent either written or electronic

Ability to adhere to the study schedule

Exclusion Criteria

You currently have a problem with using drugs or alcohol.

I do not have serious heart problems as confirmed by an ECG.

Patient is clinically unstable, in the judgment of the clinician or physician

Participant Groups

The SMART Trial is testing whether Sertraline or Bupropion is more effective for treating anhedonia in depression. It uses behavioral assessments and brain imaging to predict which antidepressant will work best before starting treatment.

Group I: MDD with SERT+ Response Marker Experimental Treatment 2 Interventions

Participants with MDD who have been classified as high sertraline responders based on behavioral and brain data.

Group II: MDD with BUP+ Response Marker Experimental Treatment 2 Interventions

Participants with MDD who have been classified as high bupropion responders based on behavioral and brain data.

Bupropion is already approved in United States, European Union, Canada, Australia for the following indications:

🇺🇸 Approved in United States as Wellbutrin for:

• Major depressive disorder
• Seasonal affective disorder
• Smoking cessation

🇪🇺 Approved in European Union as Wellbutrin for:

• Major depressive disorder
• Seasonal affective disorder
• Smoking cessation

🇨🇦 Approved in Canada as Zyban for:

• Smoking cessation

🇦🇺 Approved in Australia as Wellbutrin for:

• Major depressive disorder
• Seasonal affective disorder
• Smoking cessation

Find a Clinic Near You

Research Locations Nearby Select from list below to view details:

McLean Hospital Belmont, MA

Who Is Running the Clinical Trial?

Mclean Hospital Lead Sponsor

References